Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea—challenges and opportunities-Reference-Cited by-同舟云学术

Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea—challenges and opportunities

Published:2020-12 Issue:12 Volume:26 Page:1630-1635
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Theuretzbacher Ursula,Barbee Lindley,Connolly Kristie,Drusano George,Fernandes Prabha,Hook Edward,Jerse Ann,O'Donnell John,Unemo Magnus,Van Bambeke Françoise,VanScoy Brian,Warn Peter,Werth Brian J.,Franceschi François,Alirol Emilie

Funder

Global Antibiotic Research and Development Partnership

Reoxcyn, Inc.

Yaso Therapeutics

Microbiotix, Inc.

Venatorx, Inc

GlaxoSmithKline

Siena

Debiopharm

Merlion Pharmaceuticals

GSK

Eumedica

Shionigi Inc.

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference64 articles.

1. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016;Rowley;Bull World Health Organ,2019

2. Biological feasibility and importance of a gonorrhea vaccine for global public health;Vincent;Vaccine,2019

3. Gonorrhoea

4. World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts;Unemo;Sex Health,2019

5. Future prospects for Neisseria gonorrhoeae treatment;Suay-García;Antibiotics (Basel),2018

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. US Food and Drug Administration, Centers for Disease Control and Prevention, and National Institutes of Health Co-Sponsored Public Workshop Summary—Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea;Clinical Infectious Diseases;2024-07-24

2. Antimicrobial treatment and resistance in sexually transmitted bacterial infections;Nature Reviews Microbiology;2024-03-20

3. Pharmacodynamic evaluation of ceftriaxone single-dose therapy (0.125–1 g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoea;Journal of Antimicrobial Chemotherapy;2024-03-18

4. Evaluating the efficacy of different antibiotics against Neisseria gonorrhoeae: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation;BMC Infectious Diseases;2024-01-18

5. Study of the effects of nitroquinoline derivatives on Neisseria gonorrhoeae causative agent of the sexually transmitted infection gonorrhea;Results in Chemistry;2024-01